The bad taste was apparent in the mouth; COVID-19; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (COVID-19) and TASTE DISORDER (The bad taste was apparent in the mouth) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 066F21A, 028L20 and 026L20A) for COVID-19 vaccination.     Concurrent medical conditions included Hashimoto's thyroiditis, Penicillin allergy and Drug allergy (Erythromycin). Concomitant products included LEVOTHYROXINE SODIUM (SYNTHROID) and LIOTHYRONINE for an unknown indication.   On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 03-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 13-May-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced TASTE DISORDER (The bad taste was apparent in the mouth). In May 2022, the patient experienced COVID-19 (COVID-19). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 13-May-2022 to 18-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. On 18-May-2022, TASTE DISORDER (The bad taste was apparent in the mouth) had resolved. At the time of the report, COVID-19 (COVID-19) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 16-May-2022, SARS-CoV-2 test: negative (Negative) tested negative (rapid antigen). On 22-May-2022, SARS-CoV-2 test: positive (Positive) tested positive again with a rapid antigen test..         Company Comment: This is a spontaneous case concerning a 43-year-old female patient with no relevant medical history, who experienced the unexpected non-serious adverse event of special interest, COVID-19 which occurred approximately 6 months after receiving the third dose of mRNA-1273 Vaccine and 8 days after the treatment Nirmatrelvir, Ritonavir (Paxlovid). As reported, the patient had completed a 5-day course of treatment with Paxlovid and by the third day was feeling better but had a bad taste throughout the duration of the treatment, however 3 days post treatment the patient tested positive, no other clinical or treatment details were given. It was reported that the outcome of the event was resolving. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 43-year-old female patient with no relevant medical history, who experienced the unexpected non-serious adverse event of special interest, COVID-19 which occurred approximately 6 months after receiving the third dose of mRNA-1273 Vaccine and 8 days after the treatment Nirmatrelvir, Ritonavir (Paxlovid). As reported, the patient had completed a 5-day course of treatment with Paxlovid and by the third day was feeling better but had a bad taste throughout the duration of the treatment, however 3 days post treatment the patient tested positive, no other clinical or treatment details were given. It was reported that the outcome of the event was resolving. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.